LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC
LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a type of non-small cell lung cancer (NSCLC) in adults. The approval is for the treatment of patients whose cancer is locally advanced or metastatic and have KRAS G12C mutation, as […]